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1. Introduction  
Early diagnosis and radical management of thyroid cancer do not always result in curing 
the patient. Long-term analyses of deaths due to thyroid cancer have allowed for 
establishing systems for distinguishing increased risk groups, such as AMES or AGES. 
These commonly employed prognostic systems recognize the role of four basic factors 
only (age, stage, extent of the tumor, its size [AGES] and metastases [AMES]), which 
constitute the foundation for establishing the low and high-risk groups. Despite the 
progress in oncology and oncological surgery, a major problem still lies in early cancer 
detection, when the tumor is still at a stage that allows for curing the patient, as well as in 
identifying individuals, in whom - despite radical treatment - the prognosis of a complete 
cure is poor and there is an increased risk of a local recurrence and death due to the 
cancer.  
2. Epidemoilogy of papillary thyroid carcinoma  
Papillary thyroid carcinoma accounts for the majority of thyroid cancers and is commonly 
believed to be the least malignant type. In Europe and the United States, it presently 
constitutes approximately 75-80% of all diagnosed thyroid cancers [1]. It is characterized by 
a mild clinical course and a slow growth rate. The tumor is detected in young individuals 
(usually before they turn 40 years of age) and is 2-3 times more common in females. As a 
rule, it is a multifocal disease (in 60% of patients) involving one thyroid lobe, although in 
50% of cases microscopic neoplastic lesions are present in the contralateral lobe. One should 
be also aware of the possible presence of a small, 2-10 mm focus of papillary thyroid 
carcinoma termed „microcarcinoma”, which is asymptomatic and detected by chance in the 
course of histopathology of the thyroid gland resected in a patient with goiter or in serial 
autopsies of the thyroid (such post-mortem examinations detected 35.6% microcarcinoma 
foci). Approximately 50% of patients demonstrate the presence of metastases in the lymph 
nodes. Papillary carcinoma of the thyroid is a hormonally dependent tumor (TSH). The 5-
year survival rate is approximately 95% [2, 3]. [Fig. 1,2,3,4] 
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3. Oncogenesis  
The presently prevalent opinion states that genetic factors play an ever-increasing role in the 
development of neoplastic lesions. In view of the present knowledge, a prerequisite for 
neoplastic transformation to occur is a mutation involving two basic groups of genes - 
proto-oncogenes and suppressor genes, also called anti-oncogenes. Proto-oncogenes 
function as positive proliferation regulators. Under the effect of various external and 
internal factors, they may be converted into oncogenes. In turn, oncogene products may be 
divided into two groups of proteins, which are responsible for encoding the production of 
growth factors and affect the expression of surface receptors, either cytoplasmic or nuclear, 
thus indirectly participating in transcription inhibition or activation. Early neoplastic lesions 
usually involve a single cell line and appear as a consequence of a single or several serial 
mutations. Such mutations result in an increased capability of the cells to undergo mitotic 
divisions with a simultaneous decrease of their apoptotic capability as compared to the 
adjacent cells. Thus, a cell line develops that may give origin to for example hyperplasia of 
the thyroid tissue associated with neoplastic growth, since the borderline separating 
neoplastic transformation and hyperplastic proliferation is very thin [4,5].  
In view of the high metabolism of cells undergoing division, the growth of a non-
vascularized tumor is low. The clinical presentation of this growth phase is most commonly 
carcinoma in situ. The subsequent phase of tumor growth depends on the formation of new 
blood vessels (neoangiogenesis). Neoangiogenesis is a process composed of numerous 
interactions occurring in the paracrine and endocrine path between neoplastic cells and cells 
forming the vascular endothelium, connective tissue interstitium and some morphotic blood 
elements, such as macrophages or mastocytes. In consequence of these interactions, the 
microenvironment in the area surrounding the tumor changes, thus providing the neoplastic 
lesion with an opportunity for further uncontrollable growth and progression. A 
prerequisite for the initiation of angiogenic phenomena is a disturbed balance between the 
systems of pro- and anti-angiogenic factors. Of the identified to date proangiogenic 
factors (VEGF; bFGF; aFGF; PDGF; TGF-┙; TGF-┚; EGF; IGF-1), not all meet the three 
defining criteria: exerting a specific effect on the endothelium, possessing the system of 
specific cell receptors and inhibiting or inducing angiogenesis through changes in their 
levels. Some of these factors co-act with mediators secreted by other cells (e.g. 
macrophages - TNF) in triggering and promoting the development of neoplastic disease. 
In accordance with currently accepted theories, the initiation of angiogenesis occurs 
through hypoxia of neoplastic cells that are situated the most distally from the lumen of a 
blood vessel, as well as through a defect of the genetic apparatus, in consequence of 
which the so-called angiogenic phenotype emerges. The term denotes the condition 
characterized by a permanent, constitutional activation of genes that encode growth 
factors. An additional loss of function by suppressor genes (e.g. the p53 gene) facilitates 
neoangiogenesis [8,19,20]. [Figure 5] 
Endocrine glands constitute typical, richly vascularized organs; the circulating blood is the 
basis of their normal functioning and provides a close control of the feedback systems. As 
early as more than 20 years ago, investigators demonstrated that an increase in thyroid 
vascularization in patients with hyperthyroid goiter was regulated by cytokines secreted by 
thyreocytes. In subsequent years (reports by Goodman), the concept was confirmed and 
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extended by articles on the paracrine effect of connective tissue interstitial cells of the 
thyroid gland [17].  
The regulation of this process is complex and the contributing factors include both 
neoplastic cells capable of producing such factors as cytokines and chemokines, as well as 
immunocompetent cells situated in the vicinity of tumor cells or infiltrating the tumor itself; 
the latter also produce cytokines, chemokines and growth factors. The interrelation of such 
factor production, especially in the case of chemokines, significantly intensifies 
angiogenesis. Chemokines, which contain the repeated sequence of glutamine-leucine-
arginine, show an angiogenic activity [6-10]. 
4. Angiogenesis  
The basic process of the formation of new blood vessels originating from the previously 
existing structures is the branching off of capillary vessels and budding of new vascular 
limbs that takes place both in fetal life and in mature organisms. The process is short-lived 
(approximately 5 days on the average), subject to strict regulations, and its sudden 
termination results from the reduction of stimulatory factors and/or a decrease of inhibitor 
levels. [1-9]. Angiogenesis is a pathomechanism involved in lesions developing in 
autoimmune diseases (rheumatoid arthritis, lupus erythematosus, hemangiomas, 
scleroderma, endometriosis) and in neoplastic diseases. [11-13].  
A good part of publications in world literature on the role of angiogenic cytokines and 
epithelial growth factors in the process of tumor growth concentrate on processes occurring in 
the gastrointestinal tract [14-16]. Nevertheless, their presence and possible effect on the 
development and growth of tumors of endocrine origin have been recently recognized [17, 18].  
VEGF is among relatively well-known endothelial growth factors. This specific protein is 
believed to play a key role in vascularization of solid tumors, including thyroid cancers. In 
keeping with the theory adopted by Folkman that states that tumor growth is limited by its 
vascularization, attempts were made at demonstrating higher VEGF expression in 
neoplastic tissues as compared to the population of normal cells. These studies show such 
an association with respect to cancers involving the stomach, colon, uterus, mammary 
glands and ovaries [14-16]. Also in the case of thyroid tumors, the key role in 
neoangiogenesis is played by VEGF, especially in view of the fact that the ability to produce 
and release this factor is characteristic not only of epithelial thyroid cells, but also of 
interstitial cells [18]. 
To date, infrequent reports have dealt with peripheral blood serum VEGF determinations in 
patients with highly differentiated thyroid cancers, what has prompted us to attempt 
assessing the clinical relevance of determining the level of vascular endothelial growth 
factor (VEGF) in patients with papillary thyroid cancers.  
EGF is among the most potent stimulators of thyroid gland growth and its multiple activity 
is determined by its binding with specific EGF receptors. In vitro, EGF is a factor that 
stimulates the proliferation of follicular thyroid cells. A factor that intensifies EGF binding 
with receptors is thyreotropin (TSH), which - stimulating an increase in the number of EGF 
receptors - potentiates its activity [24,25]. In contrast to TSH, however, to reveal its 
mitogenic activity, EGF does not require the presence of other chemokines. [28]. Subsequent 
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investigators have attempted to determine the importance of positive EGF receptor 
expression in neoplastic thyroid tissue in the clinical course of the disease. EFG levels have 
been compared in various types of thyroid carcinomas and the highest expression has been 
found to be characteristic of anaplastic and medullary thyroid cancers. Also adenomas have 
been demonstrated to show marked expression of EGF receptors; however, this 
phenomenon involved solely certain regions of the tumor. The observation may weigh in 
favor of the possible neoplastic transformation of tumor tissues towards malignant 
processes [26]. The studies of Akslen et al. provided information on the importance of EGF 
receptor expression in the cytoplasm of papillary thyroid cancer cells, which was closely 
associated with extrathyroid growth of the tumor [27].  
Summing up the results of studies on the serum concentration values of selected growth 
factors - VEGF and EGF - in patients with papillary thyroid cancer, one should state that 
they both participate in the induction and progression of neoplastic processes involving the 
thyroid gland, most likely acting, however, at various stages of tumor development - VEGF 
at the stage of neoangiogenesis induction, and EGF at the stage of invasion and possible 
remote metastases formation. [Figure 6]. To provide a firm and unambiguous confirmation 
of our observations it is necessary to conduct further investigations of the angiogenic 
activity, demonstrating a correlation between microvessel density (MVD) in the primary 
and metastatic tumors, as well as the presence and expression of receptors of these 
chemokines on the one hand, and the clinical stage of the tumor on the other; and showing 
whether these growth factors indeed have a prognostic value in identifying patients with a 
poor prognosis and expected shorter recurrence-free survival.  
 
Fig. 1. Papillary thyroid cancer – psammoma body.  
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Fig. 2. Papillary thyroid cancer – a typically view 
 
Fig. 3. Papillary thyroid cancer – a microcarcinoma variant 
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Fig. 4. Papillary thyroid cancer – high positive test of CK – 19 
 
Fig. 5. Vascular growth factors and the effects of their acting.  
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Fig. 6. Correlation between VEGF, EGF and staging of papillary thyroid cancer in pTNM 
classification (r = Pearson’s correlation coefficient). The hypothesis of influence.  
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